The recommended dose is 400 mg (two 200 mg film-coated tablets) of ribociclib once daily for 21 consecutive days followed by 7 days off treatment, resulting in a complete cycle of 28 days. In …
- 文件大小: 978KB
- 页数: 54
仅显示来自 ema.europa.eu 的搜索结果Kisqali - European Medicines Agency (EMA)
The active substance in Kisqali, ribociclib, blocks the activity of enzymes known as cyclin-dependent kinases (CDK) 4 and 6, which are important f…
Kisqali - European Medicines Agency (EMA)
2017年8月31日 · The active substance in Kisqali, ribociclib, blocks the activity of enzymes known as cyclin-dependent kinases (CDK) 4 and 6, which are …
- 预计阅读时间：6 分钟
Вижте КХП на едновременно прилагания АИ, фулвестрант или lhrh агонист за указания за промяна на дозата и друга информация, свързана с безопасността, в случай на токсичност.
Моля, вижте Кратката характеристика на продукта (КХП) на ароматазния инхибитор за повече подробности. 3
KISQALI® (ribociclib) tablets, for oral use Initial U.S. Approval: 2017 -----RECENT MAJOR CHANGES----- Indications and Usage (1.1, 1.2) 09/2024 Dosage and Administration (2.1, 2.2) …
瑞博西利（ribociclib）说明书-肿瘤药品网
2021年3月10日 · 瑞博西利（ribociclib）是美国 FDA 批准的第二款的口服 CDK4 / 6 抑制剂，目前已获全球70多个国家批准。 该药最初于2017年3月和8月获美国和欧盟批准，联合一种芳香酶 …
- 其他用户还问了以下问题
Kisqali 200 mg film-coated tablets - Summary of …
Co-administration of the strong CYP3A4 inhibitor ritonavir (100 mg twice daily for 14 days) with a single 400 mg dose of ribociclib increased ribociclib exposure (AUC inf) and the peak concentration (C max) in healthy subjects 3.2 and 1.7 …
РИБОЦИКЛИБ (RIBOCICLIB) ОПИСАНИЕ
Инфекции и паразитарные заболевания: очень часто - инфекции мочевыводящих путей, инфекции дыхательных путей, гастроэнтериты, сепсис (< 1). Со стороны крови и …
Ribociclib - Wikipedia
Ribociclib, sold under the brand name Kisqali, is a medication used for the treatment of certain kinds of breast cancer. [4] Ribociclib is a kinase inhibitor. [4] It was developed by Novartis and …
Ribociclib (Kisqali) | FDA - U.S. Food and Drug Administration
On March 13, 2017, the U.S. Food and Drug Administration approved ribociclib (KISQALI, Novartis Pharmaceuticals Corp.), a cyclin-dependent kinase 4/6 inhibitor, in combination with …